Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135023 | 0.93 | AGTR1 (0.45) | LPAR1LPAR5IRAK4SMN1; SMN2ACHE | |
| SCHEMBL5138093 | 0.91 | TSHR (0.43) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5072318 | 0.90 | TSHR (0.40) | RAB9ASMN1; SMN2PTPN1 | |
| SCHEMBL5134636 | 0.87 | AGTR1 (0.46) | — | |
| SCHEMBL5134787 | 0.85 | BCHE (0.42) | — | |
| SCHEMBL5136085 | 0.84 | AGTR1 (0.45) | LPAR1LPAR5RAB9ASMN1; SMN2 | |
| SCHEMBL5135900 | 0.84 | TLR7 (0.42) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14415595 | 0.83 | HPGD (0.44) | RAB9ASMN1; SMN2 | |
| SCHEMBL5135175 | 0.83 | AGTR1 (0.43) | LPAR1LPAR5RAB9ASMN1; SMN2 | |
| SCHEMBL5134565 | 0.83 | PPARG (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |